Between Delusion and Reality: Schizophrenia A Complex Disorder
Between Delusion and Reality: Schizophrenia A Complex Disorder
Between Delusion and Reality: Schizophrenia A Complex Disorder
Introduction
Schizophrenia is a complex disorder
Behavior
Intracellular processes
Introduction
History and Phenomenology
Treponema pallidum
A psychological syndrome can be produced by an infectious agent Schizophrenia may have multiple etiologies
3
Introduction
Dementia praecox
Introduction
The Diagnostic and Statistical Manual of Mental Disorders (DSM).
Symptoms of the disorder have been present for six months or more.
Introduction
The four subtypes of schizophrenia Paranoid Catatonic Disorganized Undifferentiated Disorganized
Undifferentiated
Paranoid
Schizoaffective disorder
Catatonic
Introduction
Full Name
5,10-methylenetetrahydrofolate reductase Dopamine D4 receptor dopamine receptor D2 dopamine receptor D1 D-amino-acid oxidase interleukin 1, beta proprotein Tryptophan hydroxylase 1
Chromosome
1 11 11 5 2 2 11
TP53
HP DAOA DTNBP1 COMT
17
16 13 6 22
10
Catechol O-methyltransferase
Environmental factors
Environmental traumas associated with schizophrenia
Event
Influenza infection Starvation Traumatic brain injury
Age at event
In utero second trimester of pregnancy In utero second trimester of pregnancy Throughout life
A NEURODEVELOPMENTAL DISORDER
11
Neurotransmitters
Synapse
12
Neurotransmitters
Dopamine + Glutamate GABA Behavior, cognition, motivation, punishment, reward, sexual gratification, sleep, mood attention, learning
Dopamine
13
Neurotransmitters
Glutamate
14
Neurotransmitters
Antagonist
Blockade of NMDA receptors produces the symptomatic manifestations of schizophrenia in normal subjects, including negative symptoms and cognitive impairments.
15
Neurotransmitters
GABA
16
Perspectives
Schizophrenia in 2030
Prevention: sensitive and specific diagnostic tools
combination of approaches
Integration of care
Stigma: In contrast to many other medical disorders, schizophrenia today too often DEFINES A PERSON rather than describing the illness.
Seishin-Bunretsu-Byo (mind-split disease) change by TogoShitcho-Sho (integration disorder)
17
1. Insel T.R. 2010. Rethinking schizophrenia Nature 187 Vol 468 2. Walker E, Kestler L, Bollini A, Hochman KM. 2004 Schizophrenia: Etiology and Course Annu. Rev. Psychol. 55:40130 3. Ibrahim HM, Tamminga CA 2011. Schizophrenia: Treatment targets beyond monoamine systems. Annu. Rev. Pharmacol. Toxicol. 51:189209 4. Green MF. 2007. Stimulating the development of drug treatments to Improve cognition in schizophrenia. Annu. Rev. Clin. Psychol. 3:15980 5. Jarskog LF, Miyamoto S, Lieberman JA. 2007. Schizophrenia: New pathological insights and therapies. Annu. Rev. Med. 58:4961 6. Lewis DA, Levitt P. 2002. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25:40932 7. Carlsson A, Waters A, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. 2001 Intereactions Between monoamines, glutamato, and GABA in schizophrenia: New Evidence Annu. Rev. Pharmacol. Toxicol. 41:23760